Enzymes and Blood Clotting. II. Autoprothrombin C, Russell’s Viper Venom (Stypven), and Trypsin^[*]

Summary

In its dependence upon prothromboplastic phosphatide and calcium ions, in the conversion of prothrombin to thrombin, Autoprothrombin C is a thromboplastic enzyme. The only other demonstrated accessory factor is V, and any needs for VII, X, XI, or XII are ruled out by the present experiments, as were VIII or IX formerly. The lipid requirement may be satisfied by either phosphatidylserine (PS) or phosphatidylethanolamine (PE), purified from human blood platelets. Comparisons are made with Russell’s viper venom (“stypven”), and with trypsin. The trypsin potentiation of factors VII and X is prevented by pancreatic inhibitor (PI). However, when PI is added after this maximal potentiation, it is no longer inhibitory. The present status of knowledge concerning enzymes in relation to blood coagulation is discussed.

• References

• 1 Ferguson J. H, Erickson B. N. The coagulant action of crystalline trypsin, cephalinlung extracts. Am. J. Physiol. 126: 661 1939;
• 2 Ferguson J. H. Lipoids and Blood Platelets, with Reference to Blood Coagulation and the Hemorrhagic Diseases. Univ. N. Carolina Press. 1960: 278 Correction: p. 160 delete “VIII, IX”.
• 3 Ferguson J. H, Wilson E. G, Iatridis S. G, Rierson H. A, Johnston B. R. Enzymes and blood clotting. I. Trypsin as an accessory factor. J. clin. Invest 39: 1942 1960;
• 4 Eagle H. The coagulation of blood by snake venoms and its physiologic significance. J. exp. Med. 65: 613 1937;
• 5 Buckley E. E, Porges N. (Ed): Venoms. Publ. No. 44, Amer. Ass. Adv. Sci. Wash. D.C. 1956: 467.
• 6 Alexander B. Some biochemical, physicochemicalimmunolochemical studies of prothrombin and proconvertin (Factor VII): their biopathologic significance. Fourth Internat. Congress Biochem. 10: 37 1958;
• 7 Pechet L, Alexander B. Activation of prothrombin, factors VII and X by proteolytic pathway. Feder. Proc. 19: 64 1960;
• 8 Ferguson J. H. Methods of studying new clotting factors. Thrombos. Diathes. haemorrh. 04 Suppl. 226 1960;
• 9 Travis B. L, Ferguson J. H. Proteolytic enzyme and platelets in relation to blood coagulation. J. clin. Invest 30: 112 1951;
• 10 Iatridis S. G, Wilson E. G, Ferguson J. H, Rierson H. A. Blood clotting activities of thrombolytic agents, with special reference to a Hageman-like effect. Thrombos. Diathes. haemorrh. 05: 50 1960;
• 11 Seegers W. H. Prothrombin. Harvard Univ. Press; Cambridge, Mass: 1962: 728.
• 12 Milstone J. H. On the evolution of blood clotting theory. Medicine 31: 411 1952;
• 13 Milstone J. H. Thrombokinase of the blood as trypsin-like enzyme. J. gen. Physiol 45 No. (04) Pt. 2 (Suppl). 103 1962;
• 14 Hougie C. The role of factor V in the formation of blood thromboplastin. J. Lab. clin. Med. 50: 61 1957;
• 15 Kowarzyk H, Marciniak E, Czerwinska B. Factor V and autoprothrombin C. Arch. Immunol, i Terap. Dosw. 09: 719 1961;
• 16 Marciniak E, Seegers W. H. Autoprothrombin C: a second enzyme from prothrombin. Canad J. Biochem. 40: 596 1962;
• 17 Rapaport S. I. Evidence that glass increases plasma PTA activity. J. Lab. clin. Med. 52: 624 1958;
• 18 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J. clin. Lab. Invest 03: 201 1951;
• 19 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond). 174: 880 1954;
• 20 Marcus A. J, Ullman H. L, Wolfman M. Studies on blood platelet phospholipids. J. Lipid Res. 01: 179 1960;
• 21 Ferguson J. H, Robinson A. J. Platelet phospholipids and blood clotting. Thrombos. Diathes. haemorrh. (in press). (Stockholm Conf. Suppl.).
• 22 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple onestage antihemophilic factor assay. J. Lab. clin. Med. 41: 637 1953;
• 23 Ferguson J. H. A new blood clotting theory. Science 97: 319 1943;
• 24 Macfarlane R. G. The coagulant action of Russell’s viper venom: the use of antivenom in defining its reaction with a serum factor. Brit. J. Haemat. 07: 496 1961;
• 25 Esnouf M. P, Williams W. J. Purification, properties and activation of factor X. Thrombos. Diathes. haemorrh 07 (Suppl. 01) 213 1962;
• 26 Ferguson J. H. Coagulation balance between lipids and lipid-inhibitors in the thromboplastic mechanism. Thrombos. Diathes. haemorrh. 07 (Suppl. 01) 145 1962;
• 27 Johnston Jr. C. L, Hjort P. F. Development of increased factor VII activity during the spontaneous coagulation of blood. J. clin. Invest 40: 743 1961;
• 28 Johnston Jr. C. L, Ferguson J. H, O’Hanlon F. A, Black W. L. The fate of factor VII and Stuart factor during the clotting of normal blood. Thrombos. Diathes. haemorrh. 03: 367 1959;